Intranasal delivery to the central nervous system: Mechanisms and experimental considerations

2009/10/29 by Shyeilla V. Dhuria, Leah R. Hanson, William H. Frey · 31 citations
Pharmacology, Toxicology and Pharmaceutics · Neuroscience · #Advanced Drug Delivery Systems #Olfactory and Sensory Function Studies #Neuropeptides and Animal Physiology

paper · doi:10.1002/jps.21924

Cited by

• Systemic and Direct Nose-to-Brain Transport Pharmacokinetic Model for Remoxipride after Intravenous and Intranasal Administration
• Engineered commensals for targeted nose-to-brain drug delivery
• Intranasal drug delivery: opportunities and toxicologic challenges during drug development
• Evaluation of intranasal delivery route of drug administration for brain targeting
• Numerical Comparison of Nasal Aerosol Administration Systems for Efficient Nose-to-Brain Drug Delivery
• A Comprehensive Study on Nanoparticle Drug Delivery to the Brain: Application of Machine Learning Techniques
• Neurological impacts from inhalation of pollutants and the nose-brain connection. [europepmc]
• Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review. [europepmc]
• Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders. [europepmc]
• Intranasal administration of oxytocin: behavioral and clinical effects, a review. [europepmc]
• Particle transport and deposition: basic physics of particle kinetics. [europepmc]
• Cell based therapies for ischemic stroke: from basic science to bedside. [europepmc]
• Intranasal epidermal growth factor treatment rescues neonatal brain injury. [europepmc]
• The role of oxytocin in psychiatric disorders: a review of biological and therapeutic research findings. [europepmc]
• Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain. [europepmc]
• Adult Mesenchymal Stem Cells: When, Where, and How. [europepmc]
• Designing DNA nanodevices for compatibility with the immune system of higher organisms. [europepmc]
• Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives. [europepmc]
• Oxytocin enhances observational fear in mice. [europepmc]
• Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting. [europepmc]
• Nanoemulsions for "Nose-to-Brain" Drug Delivery. [europepmc]
• Innovative Therapy for Alzheimer's Disease-With Focus on Biodelivery of NGF. [europepmc]
• Dendrimer-Based Drug Delivery Systems for Brain Targeting. [europepmc]
• Therapeutic efficacy of nanoparticles and routes of administration. [europepmc]
• Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage. [europepmc]
• Intranasal drug delivery: opportunities and toxicologic challenges during drug development. [europepmc]
• Neuroprotective Herbs for the Management of Alzheimer's Disease. [europepmc]
• Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: A current overview of in vivo studies. [europepmc]
• Nanotherapeutics for Nose-to-Brain Drug Delivery: An Approach to Bypass the Blood Brain Barrier. [europepmc]
• Overcoming the blood-brain barrier for the therapy of malignant brain tumor: current status and prospects of drug delivery approaches. [europepmc]
• Alzheimer's Disease: Treatment Strategies and Their Limitations. [europepmc]